MRTX - Mirati Therapeutics GAAP EPS of -$3.18 beats by $0.41 revenue of $7.17M beats by $2.37M
2023-05-09 16:30:54 ET
- Mirati Therapeutics press release ( NASDAQ: MRTX ): Q1 GAAP EPS of -$3.18 beats by $0.41 .
- Revenue of $7.17M (+909.9% Y/Y) beats by $2.37M .
- Net reduction in cash, cash equivalents and short-term investments for the first quarter was $181.5 million, which included 2022 annual bonus payments and a one-time cash payment of $15 million to Pfizer. The Company expects 2023 net cash burn to annualize within a range of $525 million to $580 million.
For further details see:
Mirati Therapeutics GAAP EPS of -$3.18 beats by $0.41, revenue of $7.17M beats by $2.37M